Second line immune checkpoint inhibition in urothelial cancer
Status PubMed-not-MEDLINE Language English Country China Media print
Document type Editorial, Comment
PubMed
31807418
PubMed Central
PMC6842776
DOI
10.21037/tau.2019.09.18
PII: tau-08-05-414
Knihovny.cz E-resources
Department of Special Surgery University of Jordan Amman Jordan
Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic
Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria
Department of Urology Luzerner Kantonsspital Lucerne Switzerland
Department of Urology University of Texas Southwestern Dallas TX USA
Department of Urology Weill Cornell Medical College New York NY USA
Division of Urology Azienda Ospedaliera Città della Salute e della Scienza di Torino Torino Italy
See more in PubMed
Hautmann RE, de Petriconi RC, Pfeiffer C, et al. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol 2012;61:1039-47. 10.1016/j.eururo.2012.02.028 PubMed DOI
Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001;19:2638-46. 10.1200/JCO.2001.19.10.2638 PubMed DOI
von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23:4602-8. 10.1200/JCO.2005.07.757 PubMed DOI
Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009;27:4454-61. 10.1200/JCO.2008.20.5534 PubMed DOI
Bellmunt J, Fougeray R, Rosenberg JE, et al. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol 2013;24:1466-72. 10.1093/annonc/mdt007 PubMed DOI
Necchi A, Pond GR, Raggi D, et al. Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis. Clin Genitourin Cancer 2017;15:23-30.e2. 10.1016/j.clgc.2016.05.003 PubMed DOI
Shariat SF, Gust KM. Immune therapy meets precision medicine. Lancet Oncol 2017;18:271-3. 10.1016/S1470-2045(17)30098-0 PubMed DOI
Balar AV, Castellano DE, O'Donnell PH, et al. Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population. J Clin Oncol 2017;35:abstr 284.
Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017;389:67-76. 10.1016/S0140-6736(16)32455-2 PubMed DOI PMC
Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med 2017;376:1015-26. 10.1056/NEJMoa1613683 PubMed DOI PMC
Fradet Y, Bellmunt J, Vaughn DJ, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of > 2 years of follow-up. Ann Oncol 2019. [Epub ahead of print]. 10.1093/annonc/mdz127 PubMed DOI PMC
Patel MR, Ellerton J, Infante JR, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol 2018;19:51-64. 10.1016/S1470-2045(17)30900-2 PubMed DOI PMC
Powles T, Duran I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018;391:748-57. 10.1016/S0140-6736(17)33297-X PubMed DOI
Powles T, O'Donnell PH, Massard C, et al. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. JAMA Oncol 2017;3:e172411. 10.1001/jamaoncol.2017.2411 PubMed DOI PMC
Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2017;18:312-22. 10.1016/S1470-2045(17)30065-7 PubMed DOI
Loriot Y, Necchi A, Park SH, et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med 2019;381:338-48. 10.1056/NEJMoa1817323 PubMed DOI
Rosenberg JE, O'Donnell PH, Balar AV, et al. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. J Clin Oncol 2019;37:2592-600. 10.1200/JCO.19.01140 PubMed DOI PMC
Necchi A, Anichini A, Raggi D, et al. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. J Clin Oncol 2018:JCO1801148. [Epub ahead of print] PubMed
Powles T, Rodriguez-Vida A, Duran I, et al. A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS). J Clin Oncol 2018;36:abstr 4506.
Gust KM, Shariat SF. Re: Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Carcinoma (PURE-01): An Open-label, Single-arm, Phase II Study. Eur Urol 2019;75:695-6. 10.1016/j.eururo.2018.12.034 PubMed DOI
Galsky MD, Hahn NM, Rosenberg J, et al. Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. J Clin Oncol 2011;29:2432-8. 10.1200/JCO.2011.34.8433 PubMed DOI
FDA. Available online: https://www.fda.gov/drugs/drugsafety/ucm608075.htm, 2018.
EMA. EMA/364553/2018. Available online: https://www.ema.europa.eu/en/documents/press-release/ema-restricts-use-keytruda-tecentriq-bladder-cancer_en.pdf, 2018.
Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909-20. 10.1016/S0140-6736(16)00561-4 PubMed DOI PMC
Powles T, Loriot Y, Ravaud A, et al. Atezolizumab vs Chemotherapy in Platinum-Treated Locally Advanced or Metastatic Urothelial Carcinoma: Immune Biomarker, Tumor Mutational Burden and Clinical Outcomes From the Phase III IMvigor 211 Study. J Clin Oncol 2018;36:abstr 409.
